Onyx Pharma – Kyprolis to Accelerate Growth
ODAC panel’s favorable review (11-0 in favor of accelerated approval) for Kyprolis (carfilzomib – CFZ, R, next-generation proteasome inhibitor) pushed ONXX’s stock to the North and further fuel takeover rumor. The panel weighed the serious adverse events – cardiovascular toxicities and deaths associated with Kyprolis as expected. ONXX has finally succeeded in diversifying its pipeline – three launched/ to be launched drugs in its portfolio- Nexavar (L, RCC, HCC, partnered with Bayer), Kyprolis, and Regorafenib (R, oral multi-kinase inhibitor, GIST, mCRC Filed). Kyprolis (PDUFA: July 27, 2012 for R/R MM), once approved will have the first... For more detail, please read our report released on Jun 21, 2012 on Onyx Pharma titled “Onyx Pharma - Kyprolis to Accelerate Growth”
COMPANIES MENTIONED
Onyx Pharma
Onyx Pharma
More Publications
Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!
US$ 90.00
March 2012
4 pages
Onyx Pharma - ASCO ’12: Kyprolis’ Data enough to obtain an ‘Accelerate Approval’?
US$ 90.00
May 2012
4 pages
Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
US$ 90.00
November 2011
6 pages
ONYX PHARMA - Testing Time Ahead in the Hematological Cancer Space
US$ 140.00
September 2011
3 pages
ONYX PHARMA - Carfilzomib Approval - Now or Later?
US$ 140.00
November 2011
3 pages
